Introduction {#Sec1}
============

Exaggerated impulsive behavior very often has undesirable consequences. As such, impulsivity is prominent in the symptomatology of a variety of psychiatric disorders such as attention deficit/hyperactivity disorder (ADHD), drug addiction, problem gambling, mania and personality disorders (American Psychiatric Association [@CR1]; Chamberlain and Sahakian [@CR18]; Moeller et al. [@CR57]). Moreover, impulsivity may be a behavioral marker for enhanced vulnerability to drug addiction. Poor response inhibition or enhanced impulsive decision making predisposes adolescents for smoking, alcoholism and substance abuse (Audrain-McGovern et al. [@CR4]; Nigg et al. [@CR62]). Consistently, animal studies have shown that high impulsivity predicts the vulnerability to alcohol consumption, cocaine self-administration and nicotine-seeking behavior (Dalley et al. [@CR27]; Diergaarde et al. [@CR31]; Perry et al. [@CR69]; Poulos et al. [@CR70]). It is now widely recognized that impulsivity consists of various, mostly independent behavioral dimensions that can be neuroanatomically and neuropharmacologically dissociated (Dalley et al. [@CR28]; Eagle and Baunez [@CR32]; Evenden [@CR34]; Pattij and Vanderschuren [@CR67]; Winstanley [@CR94]). In general, two main subtypes of impulsive behavior are distinguished, i.e., impulsive choice and impulsive action. Impulsive choice refers to the inability to delay gratification, which is behaviorally apparent as a preference for a small, immediate gain over a larger reward that one has to wait for. Impulsive action comprises behavior resulting from a deficit in the ability to withhold responding or stop ongoing behavior. Both behavioral subtypes of impulsivity appear in the patient population and these can be studied in preclinical models with high translational value (Evenden [@CR34]; Moeller et al. [@CR57]; Solanto et al. [@CR81]; Winstanley [@CR94]).

Different classes of drugs are used in the treatment of disorders characterized by disrupted impulse regulation such as ADHD, personality disorders and problem gambling. The psychostimulant drugs amphetamine (Adderall™) and methylphenidate (Ritalin™, Concerta™) are the first-choice treatment for ADHD, whereas the selective noradrenaline reuptake inhibitor atomoxetine (Strattera®) is a widely used alternative (Biederman and Faraone [@CR8]). The therapeutic use of these drugs has sparked great interest in the role of monoaminergic neurotransmission in impulsivity. The primary mode of action of amphetamine is to enhance monoaminergic neurotransmission by blocking the reuptake and evoking the release of dopamine (DA), noradrenaline (NA) and, to a lesser extent, serotonin (5-hydroxytryptamine, 5-HT) (Kuczenski and Segal [@CR46]; Kuczenski et al. [@CR47]; Ritz and Kuhar [@CR72]; Rothman et al. [@CR75]; Seiden et al. [@CR77]; Sulzer et al. [@CR85]). Administration of amphetamine has been shown to decrease impulsive choice in delay-discounting paradigms (Barbelivien et al. [@CR5]; Cardinal et al. [@CR15]; De Wit et al. [@CR29]; Isles et al. [@CR43]; Richards et al. [@CR71]; Sun et al. [@CR86]; Van Gaalen et al. [@CR89]; Wade et al. [@CR92]; Winstanley et al. [@CR95], but see Evenden and Ryan [@CR35]) but to increase premature responding, an index of impulsive action, in the five-choice serial reaction time task (5-CSRTT; Cole and Robbins [@CR20]; [@CR21]; Harrison et al. [@CR40]; Murphy et al. [@CR59]; Paterson et al. [@CR66]; Pattij et al. [@CR68]; Sun et al. [@CR86]; Van Gaalen et al. [@CR88]). Pharmacological analysis of the effects of amphetamine has indicated that DA neurotransmission plays an important, opposing role in the modulation of impulsive action and impulsive choice (Cole and Robbins [@CR21]; Pattij et al. [@CR68]; van Gaalen et al. [@CR88], [@CR89], [@CR90]). Atomoxetine is a potent NA reuptake inhibitor with no appreciable affinity for the DA or 5-HT transporter (Bolden-Watson and Richelson [@CR12]), which has been shown to be effective in the treatment of ADHD (Kratochvil et al. [@CR45]; Simpson and Perry [@CR79]; Spencer et al. [@CR84]; Wilens et al. [@CR93]). Although selective inhibition of NA reuptake has been reported to have beneficial effects on impulsive action in the 5-CSRTT (Blondeau and Dellu-Hagedorn [@CR11]; Navarra et al. [@CR60]; Paine et al. [@CR64]; Paterson et al. [@CR66]; Robinson et al. [@CR74]; Sun et al. [@CR86]; Van Gaalen et al. [@CR88]), its effects on impulsive choice are inconclusive (Robinson et al. [@CR74]; Sun et al. [@CR86]; Van Gaalen et al. [@CR89]). Interestingly, 5-HT was the first neurotransmitter system to be implicated in impulsivity (Linnoila et al. [@CR50]; Soubrié [@CR83]). Selective 5-HT reuptake inhibitors (SSRIs) are not regularly prescribed as therapeutic drugs for ADHD (Biederman and Faraone [@CR8]; Elia et al. [@CR33]; Fone and Nutt [@CR38]; Kutcher et al. [@CR48]), although they are used for the treatment of other disorders associated with poor impulse control such as problem gambling, sexual addiction, personality disorders and impulsive aggression (Coccaro and Kavoussi [@CR19]; Hollander and Rosen [@CR41]). Remarkably, the effects of SSRIs on different forms of impulsive behavior have not been characterized in depth (Bari et al. [@CR6]; Evenden and Ryan [@CR35]).

Although the role of monoamine neurotransmission in impulsive behavior has been widely investigated, several caveats remain. First, as mentioned above, the consequences of selective blockade of the 5-HT transporter for impulsive behavior are largely unknown. Second, beneficial effects of selective NA reuptake inhibitors on impulsive action (as assessed in the 5-CSRTT and stop signal task) have been consistently reported by different studies, but its effects on impulsive choice are inconclusive. Third, in studies on impulsive action using the 5-CSRTT, well-trained animals are used, which often display very low levels of impulsivity. This makes it easy to detect impairments in impulse control but leaves relatively little room to observe reductions in premature responding, which is most relevant from a therapeutic point of view. The present study sought to further characterize the role of monoamine neurotransmission in impulsive behavior, taking these caveats into account. To that aim, we investigated the effects of selective inhibitors of the reuptake of DA (GBR12909), NA (atomoxetine) and 5-HT (citalopram) on two main behavioral dimensions of impulsivity in rats. Impulsive action was studied using the 5-CSRTT (Carli et al. [@CR17]; Robbins [@CR73]), and the delayed reward task (DRT; Evenden and Ryan [@CR35]) was used to measure impulsive choice. Amphetamine was also included as its effects on impulsive behavior have been well described (Eagle and Baunez [@CR32]; Pattij and Vanderschuren [@CR67]). To increase the possibility to observe drug-induced reductions in impulsive action, we performed neuropharmacological challenges in the 5-CSRTT under both baseline as well as long intertrial interval (ITI) conditions. The use of a long ITI, in which the animal unexpectedly has to wait longer for the instruction signal to appear, enhances levels of impulsive action in the 5-CSRTT (Dalley et al. [@CR26]; Navarra et al. [@CR60]; Paterson et al. [@CR66]). Not only does a long ITI evoke higher levels of premature responding, it may also be that performance under baseline conditions relies on different neural and cognitive processes than responding under novel, challenging circumstances. For example, NA neurotransmission appears to be especially engaged when task contingencies unexpectedly change (Cole and Robbins [@CR22]; Dalley et al. [@CR25]; Sirviö et al. [@CR80]). Thus, drug effects under baseline and long ITI conditions in the 5-CSRTT may be qualitatively or quantitatively different.

Materials and methods {#Sec2}
=====================

Subjects {#Sec3}
--------

Male Lister Hooded rats (Harlan CPB, Horst, The Netherlands), weighing 200--250 g at the beginning of the experiment, were housed two per cage under reversed lighting conditions (lights on from 19.00 to 07.00 h). After 2 weeks of habituation, rats were placed on a restricted diet of 14 g of standard rat chow per day and body weights were monitored on a weekly basis. Feeding occurred in the rats\' home cages at the end of the experimental day. All experiments were approved by the Animal Ethics Committee of Utrecht University and were conducted in agreement with Dutch laws (Wet op de Dierproeven, 1996) and European regulations (Guideline 86/609/EEC).

Behavioral apparatus {#Sec4}
--------------------

Behavioral testing for all experiments was conducted in 16 identical operant conditioning chambers (30.5 × 24 × 21 cm; Med Associates, St. Albans, VT, USA) enclosed in sound attenuating boxes. The boxes were equipped with a fan to provide ventilation and to mask extraneous noise. Set in the curved wall of each box was an array of five holes. Each nose poke unit was equipped with an infrared detector and a yellow light-emitting diode stimulus light. Food pellets (45 mg, Formula P; Bio-Serv) could be delivered at the opposite wall via a dispenser. The chamber could be illuminated by a white house light mounted in the center of the roof. Online control of the apparatus and data collection were performed using MED-PC version 1.17 (Med Associates).

Behavioral procedures {#Sec5}
---------------------

A detailed description of the 5-CSRTT and DRT procedure has been provided previously (Van Gaalen et al. [@CR88]; Van Gaalen et al. [@CR89], respectively). Separate groups of animals were trained for each experiment. For both behavioral paradigms, similar habituation and magazine training protocols were followed. This protocol consisted of a habituation exposure to the operant chambers for two daily 30-min sessions, during which sucrose pellets were placed in the response holes and food magazine. Subsequently, in the next two sessions, a total of 75 pellets were delivered with a random interval to allow the animals to associate the sound of pellet delivery with reward. This procedure was followed by magazine shaping, in which animals were trained to make a nose poke into an illuminated response hole to earn reward. The spatial location of the stimulus lights was adjusted according to the experimental paradigm. Each session of magazine training consisted of 100 trials and lasted approximately 30 min. Five sessions were scheduled per week (one session per day, Monday--Friday) during the dark phase of the light/dark cycle.

### Five-choice serial reaction time task {#Sec6}

Rats were trained to detect and respond to a brief visual stimulus presented randomly in one of the five nose poke units to obtain a food reward. A trial started with an ITI of 5 s, followed by 1-s illumination of one of the five apertures and 2-s limited hold. Following a nose poke in the illuminated aperture, i.e., a correct response, animals were rewarded with the delivery of one food pellet (45 mg, Formula P, Research Diets) in the food magazine. During the training session, stimulus duration was set at 32 s and was gradually decreased over sessions to 1 s until animals reached stable baseline performance (accuracy, \>80% correct choice and \<20% errors of omission). Each daily session consisted of 100 discrete trials or 30 min, whichever occurred first. A nose-poke response into a nonilluminated aperture, i.e., an incorrect response as well as failure to respond within 5 s after the onset of the stimulus, i.e., an error of omission, resulted in no food delivery and a time-out period with the house light extinguished for 5 s. Nose pokes made during the ITI, i.e., before the onset of the stimulus (premature responses) were recorded as a measure of impulsivity and resulted in a 5 s time-out and no food reward. Perseverative responses, i.e., repeated responding during the presentation of the stimulus, were measured but did not have any programmed consequences. The following behavioral measures were recorded: (1) premature responses, i.e., number of responses into one of the holes during the ITI preceding stimulus presentation; (2) accuracy, i.e., percentage of correct responses \[(number correct responses) / (correct + incorrect responses) × 100\]; (3) latency of correct responses, i.e., the mean time between stimulus onset and nose poke in the illuminated unit; (4) omission errors, i.e., the total number of omitted trials during a session; and (5) perseverative responses after correct choice.

Following acute drug administration under baseline conditions, a cohort of rats was used for pharmacological manipulation under long ITI conditions. During these sessions, the ITI was extended to 7 s to provoke impulsive behavior (Dalley et al. [@CR26]). The long ITI session consisted of 100 trials (ITI 7 s, stimulus duration 0.5 s) per session and was repeated once a week. The long ITI days were at all times preceded and followed by two baseline days (ITI 5 s, stimulus duration 0.5 s) to avoid habituation to the long ITI.

### Delayed reward paradigm {#Sec7}

Rats were faced with a choice between a small, immediate food reward and a larger but delayed food reward. Ultimately, the delayed option is more beneficial, but the subjective value of the large food reward declines with increasing delay to its delivery (Logue [@CR51]).

In the final stage of the task, a session was divided into five blocks of 12 trials. Each block started with two forced trials in which, after initiating the trial by a nose poke into the center hole, either the left or the right hole was illuminated in a counterbalanced fashion. For the next 10 trials, the animals had a free choice and both the left and right units were illuminated. Nose poking into one position resulted in the immediate delivery of a small reinforcer (one food pellet), whereas a nose poke into the other position resulted in the delivery of a large, but delayed, reinforcer (four food pellets). Over sessions, the delays for the large reinforcer were progressively increased within a session from 0 to 10, 20, 40 and 60 s per block. After delivery of the reinforcer or the choice phase time elapsed, an ITI commenced until the next trial started. As the trial time was fixed, the ITI duration depended on the duration of the delay. The positions associated with the small and large reinforcers were always the same for each individual but counterbalanced for the group. The behavioral measure to assess task performance, i.e., the percentage preference for the large reinforcer as a function of delay, was calculated as the \[(number of choices for the large reinforcer) / (number choices large + small reinforcers) × 100\]. Furthermore, no response during the choice phase within 10 s was counted as an omission and the total number of omitted choice trials per block of 10 trials within a session was calculated.

Drugs {#Sec8}
-----

(+)-Amphetamine sulphate was purchased from O.P.G. (Utrecht, The Netherlands). GBR12909 dihydrochloride, atomoxetine hydrochloride and citalopram hydrobromide were obtained from Tocris Bioscience (UK). All drug doses were calculated as salt, dissolved in 0.9% saline (amphetamine, atomoxetine, and citalopram) or sterile water (GBR12909). Drugs were freshly prepared each day before testing and injected intraperitoneally (i.p.) in a volume of 1 ml/kg body weight. Drug tests were conducted on Tuesdays and Fridays with baseline training sessions on the other weekdays. Before the first test day, all animals had been habituated twice to i.p. saline injections. Drugs were administered according to a Latin square design and each animal received a maximum of two different drugs. In addition, in a subgroup of rats pharmacological manipulations were tested in the 5-CSRTT under a long ITI of 7 s once a week according to a Latin square design with baseline training sessions (intertrial interval of 5 s) in between.

Statistical analysis {#Sec9}
--------------------

All data are presented as means and standard errors of the mean and analyzed using SPSS for Windows, version 15.0. The data of the delayed reward task were subjected to an arcsin transformation before statistical analysis (McDonald [@CR53]). In the DRT, animals that did not show a delay-dependent curve in their choice behavior (0% choice for large reward at 0 s delay, 100% choice for large reward at 40 and 60 s delay) were excluded from the experiment. Data were analyzed by one- (5-CSRTT) or two-factor (DRT) repeated-measures ANOVAs with drug treatment (5-CSRTT, DRT) and delay to large reinforcer (DRT) as within-subjects variables. If the outcome of the repeated-measures ANOVA yielded significant effects of dose or dose × delay at *p* \< 0.05 level, further post-hoc analysis was performed using paired samples *t*-tests. Pharmacological effects on 5-CSRTT performance under a long ITI were analyzed using paired samples *t*-tests (vehicle versus drug treatment).

Results {#Sec10}
=======

Effect of amphetamine and monoamine reuptake inhibitors on 5-CSRTT performance under baseline conditions {#Sec11}
--------------------------------------------------------------------------------------------------------

As depicted in Fig. [1a](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}, amphetamine significantly increased the number of premature responses and perseverative responses in the 5-CSRTT \[*F*(3,45) = 13.12, *p* \< 0.001 and *F*(3,45) = 3.64, *p* \< 0.05, respectively\]. Post-hoc analysis revealed that the increase of premature and perseverative responses was significant at all tested doses (*p* \< 0.01 and *p* \< 0.05, respectively). In addition to the effect on impulsivity, systemic administration of amphetamine reduced accuracy, i.e., percentage of correct responses at all doses \[*F*(3,45) = 8.82, *p* \< 0.001\], whereas the response latency was only reduced at a dose of 0.5 mg/kg (Table [1](#Tab1){ref-type="table"}) \[*F*(3,45) = 3.37, *p* \< 0.05\]. Errors of omission were differentially affected by amphetamine; as 0.25 mg/kg of amphetamine reduced the amount of errors of omission, no effect was found at the intermediate dose of 0.5 mg/kg and 1 mg/kg of amphetamine resulted in a significant increase (Table [1](#Tab1){ref-type="table"}) \[*F*(3,45) = 10.49, *p* \< 0.001\].Fig. 1Effects of amphetamine (**a**), the selective DA reuptake inhibitor GBR12909 (**b**), the selective NA reuptake inhibitor atomoxetine (**c**) and the selective 5-HT reuptake inhibitor citalopram (**d**) on premature responding, i.e., impulsive action under baseline conditions (visual stimulus presented 5 s after trial initiation) in the 5-CSRTT. In total, *n* = 16 animals were included in the analysis. *Asterisk* indicates *p* \< 0.05 and *two asterisks* indicates *p* \< 0.01 compared to vehicle treatment (paired samples *t*-test). All data are expressed as mean ± SEMTable 1Effects of amphetamine, GBR12909, atomoxetine and citalopram on behavioral performance (accuracy, omissions, premature and perseverative responses, response latency) under baseline conditions (visual stimulus presented 5 s after trial initiation) in the 5-CSRTT. In total, *n* = 16 animals were included in the analysis. \**p* \< 0.05 and \*\**p* \< 0.01 compared to vehicle treatment (paired samples *t*-test). All data are expressed as mean ± SEMCorrect responsesErrors of omissionPremature responsesPerseverative responsesResponse latency (s)AmphetamineVeh90.8 ± 1.417.9 ± 1.66.3 ± 1.013.8 ± 2.40.71 ± 0.030.25 mg/kg85.2 ± 2.2\*12.4 ± 1.3\*18.4 ± 4.4\*\*23.7 ± 4.9\*0.66 ± 0.020.5 mg/kg82.9 ± 2.3\*16.2 ± 2.324.0 ± 4.1\*\*23.8 ± 5.7\*0.6 ± 0.02\*1.0 mg/kg79.1 ± 2.3\*32.5 ± 5.2\*\*36.3 ± 6.0\*\*29.2 ± 6.6\*0.71 ± 0.03GBR12909Veh90.7 ± 1.114.6 ± 2.15.3 ± 0.86.7 ± 1.10.67 ± 0.022.5 mg/kg91.2 ± 1.215.8 ± 2.74.8 ± 0.75.9 ± 0.70.67 ± 0.025.0 mg/kg89.0 ± 1.411.6 ± 1.88.9 ± 2.47.9 ± 1.60.64 ± 0.02\*10.0 mg/kg85.3 ± 2.3\*\*10.2 ± 1.929.9 ± 8.2\*\*21.4 ± 4.9\*\*0.61 ± 0.02\*\*AtomoxetineVeh91.0 ± 1.518.4 ± 2.26.4 ± 1.514.6 ± 4.20.73 ± 0.030.3 mg/kg94.6 ± 1.425.8 ± 2.5\*3.2 ± 1.211.0 ± 2.30.81 ± 0.04\*\*1.0 mg/kg94.3 ± 1.033.4 ±3.0\*\*3.5 ± 0.910.9 ± 1.90.84 ± 0.04\*\*3.0 mg/kg94.5 ±1.644.3 ± 2.8\*\*3.5 ± 0.910.2 ± 2.40.96 ± 0.04\*\*CitalopramVeh91.7 ± 1.012.8 ± 2.15.1 ± 0.87.0 ± 1.70.66 ± 0.020.3 mg/kg91.7 ± 1.315.8 ± 2.64.8 ± 0.97.1 ± 1.10.68 ± 0.021.0 mg/kg92.2 ± 1.216.4 ± 2.62.6 ±0.4\*4.1 ± 1.10.69 ± 0.02\*3.0 mg/kg92.5 ± 1.216.6 ± 2.23.1 ± 0.77.4 ± 1.50.70 ± 0.02\*

Systemic administration of the selective DA reuptake inhibitor GBR12909 resulted in enhanced premature and perseverative responses at a dose of 10 mg/kg (Fig. [1b](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}) \[*F*(3,45) = 8.46, *p* \< 0.007 and *F*(3,45) = 10.26, *p* \< 0.004, respectively\]. At this dose, the percentage of correct responses and response latency were reduced (Table [1](#Tab1){ref-type="table"}) \[*F*(3,45) = 6.02, *p* \< 0.01 and *F*(3,45) = 3.93, *p* = 0.01, respectively\]. GBR12909 had no effect on errors of omission \[*F*(3,45) = 2.23, NS\].

Atomoxetine, the selective NA reuptake inhibitor, enhanced the errors of omission and slowed response latency at all tested doses without affecting impulsive behavior (Fig. [1c](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}) \[*F*(3,45) = 26.43, *p* \< 0.001, *F*(3,45) = 23.22, *p* \< 0.001, *F*(3,45) = 2.54, NS, respectively\]. The other parameters of 5-CSRTT performance were unaffected by atomoxetine treatment under baseline conditions \[correct responses: *F*(3,45) = 2.23, NS and perseverative responses: *F*(3,45) = 0.8, NS\].

Premature responding was decreased after treatment with the selective 5-HT reuptake inhibitor citalopram at the intermediate dose of 1.0 mg/kg (Fig. [1d](#Fig1){ref-type="fig"}) \[*F*(3,45) = 2.98, *p* \< 0.05\], whereas the response latency was increased at a dose of 1.0 mg/kg and 3.0 mg/kg \[*F*(3,45) = 2.79, *p* = 0.05\]. Further comparisons indicated that accuracy, errors of omissions and perseverative responses were unaffected by citalopram \[*F*(3,45) = 0.23, NS, *F*(3,45) = 0.99, NS, *F*(3,45) = 1.97, NS, respectively\].

Effect of amphetamine and monoamine reuptake inhibitors on 5-CSRTT performance under long ITI conditions {#Sec12}
--------------------------------------------------------------------------------------------------------

Under long ITI conditions in the 5-CSRTT, the effects of monoamine reuptake inhibitors were tested at a dose that affected impulsive behavior under baseline conditions, i.e., 10 mg/kg GBR12909 and 1 mg/kg citalopram. For atomoxetine, which did not alter impulsive behavior under baseline conditions, the highest dose was used (i.e., 3 mg/kg). An intermediate dose of amphetamine (0.5 mg/kg) was used as this dose had no effect on the errors of omission under baseline conditions but did markedly increase impulsive behavior in the 5-CSRTT (Table [1](#Tab1){ref-type="table"}).

Similar to baseline conditions, amphetamine (0.5 mg/kg) and GBR12909 (10 mg/kg) increased the amount of premature and perseverative responses and attenuated accuracy under long ITI conditions (Fig. [2a](#Fig2){ref-type="fig"}, b) \[premature responses: *df* = 15, *t* = −4.07, *p* = 0.001 and *df* = 14, *t* = −3.49, *p* = 0.01, perseverative responses: *df* = 15, *t* = −3.21, *p* \< 0.01 and *df* = 14, *t* = −2.50, *p* \< 0.05, correct responses: *df* = 15, *t* = 2.70, *p* \< 0.05 and *df* = 14, *t* = 2.52, *p* \< 0.05, respectively\]. In addition, GBR12909 (10 mg/kg) decreased response latency, whereas amphetamine had no effect on this parameter \[*df* = 14, *t* = 2.91, *p* = 0.01 and *df* = 15, *t* = −0.44, NS, respectively\]. No effect of amphetamine and GBR12909 was observed on errors of omission \[*df* = 15, *t* = −0.65, NS and *df* = 14, *t* = 0.66, NS\].Fig. 2Effects of amphetamine (**a**), the selective DA reuptake inhibitor GBR12909 (**b**), the selective NA reuptake inhibitor atomoxetine (**c**) and the selective 5-HT reuptake inhibitor citalopram (**d**) on 5-CSRTT performance under long ITI conditions (visual stimulus presented 7 s after trial initiation). In total, *n* = 15 animals were included in the analysis. *Asterisk* indicates *p* \< 0.05 and *two asterisks* indicates *p* \< 0.01 compared to vehicle treatment (paired samples *t*-test). All data are expressed as mean ± SEM

Atomoxetine (3 mg/kg) reduced premature and perseverative responding under long ITI conditions (Fig. [2c](#Fig2){ref-type="fig"}) \[*df* = 15, *t* = 6.0, *p* \< 0.001 and *df* = 15, *t* = 4.47, *p* \< 0.001, respectively\]. Additional comparisons revealed that all other parameters of 5-CSRTT were enhanced by atomoxetine under these conditions (Fig. [2c](#Fig2){ref-type="fig"}) \[correct responses: *df* = 15, *t* = −2.97, *p* = 0.01; omissions: *df* = 15, *t* = −2.33 *p* \< 0.05; response latency: *df* = 15, *t* = −2.26, *p* \< 0.05\].

Premature and perseverative responses were both reduced by citalopram (1 mg/kg) pretreatment under long ITI conditions (Fig. [2d](#Fig2){ref-type="fig"}) \[premature responses: *df* = 15, *t* = 4.28, *p* = 0.001, perseverative responses: *df* = 15, *t* = 2.49, *p* \< 0.05\]. Under these conditions, citalopram did not affect accuracy, errors of omission and response latency \[correct responses: *df* = 15, *t* = −0.22, NS, omissions: *df* = 15, *t* = −0.19, NS and response latency: *df* = 15, *t* = 1.26, NS\].

Effect of amphetamine and monoamine reuptake inhibitors on impulsive choice in the DRT {#Sec13}
--------------------------------------------------------------------------------------

Overall, animals showed a delay-dependent decline in their choice behavior for the large, delayed reward \[vehicle, delay: *F*(4,48) = 31.49, *p* \< 0.001\]. Amphetamine significantly enhanced the preference for the large delayed reward \[dose: *F*(3,36) = 3.11, *p* \< 0.05; dose × delay: *F*(12,144) = 1.33, NS\], and post-hoc analysis revealed that this effect was significant for all doses of amphetamine at the 40-s delay and for 0.5 and 1 mg/kg amphetamine at a delay of 60 s (Fig. [3a](#Fig3){ref-type="fig"}).Fig. 3Effects of amphetamine (**a**), the selective DA reuptake inhibitor GBR12909 (**b**), the selective NA reuptake inhibitor atomoxetine (**c**) and the selective 5-HT reuptake inhibitor citalopram (**d**) on the percentage choice for the large reinforcer in the delayed reward paradigm. In total, *n* = 13--15 animals were included in the analysis. *Asterisk* indicates *p* \< 0.05 and *two asterisks* indicates *p* \< 0.01 compared to vehicle treatment (paired samples *t*-test). All data are expressed as mean ± SEM

The selective DA reuptake inhibitor GBR12909 also increased the preference for the larger delayed reward \[dose: *F*(3,39) = 11.07, *p* \< 0.001; dose × delay: *F*(12,156) = 2.29, *p* = 0.01\]. Post-hoc analysis of the data showed a significant effect of 10 mg/kg of GBR12909 on all delays, i.e., 10, 20, 40 and 60 s (Fig. [3b](#Fig3){ref-type="fig"}). At a dose of 5 mg/kg, GBR12909 resulted in an increased preference for the large reward at the delay of 10 and 20 s (Fig. [3b](#Fig3){ref-type="fig"}).

The selective NA reuptake inhibitor atomoxetine did not alter choice behavior in the DRT at any delay \[dose: *F*(3,39) = 0.31, NS; dose × delay: *F*(12,156) = 1.64, NS\].

The selective 5-HT reuptake inhibitor citalopram also did not affect choice behavior in the DRT (Fig. [3d](#Fig3){ref-type="fig"}) \[dose: *F*(3,39) = 1.27, NS; dose × delay: *F*(12,156) = 1.11, NS\].

Discussion {#Sec14}
==========

In order to advance our understanding of the role of monoamine neurotransmission in impulse control, the present study investigated the effects of selective monoamine reuptake inhibitors on two behavioral dimensions of impulsivity, i.e., impulsive action in the 5-CSRTT and impulsive choice in the DRT. Besides comparing three selective monoamine reuptake inhibitors and amphetamine in two separate measures of impulsivity within a single study, we aimed to address several outstanding questions with regard to monoamine neurotransmission and impulsive behavior. Thus, we have shown that the 5-HT reuptake blocker citalopram selectively reduces premature responding in the 5-CSRTT but does not affect impulsive choice in the DRT. In addition, the NA reuptake inhibitor atomoxetine reduced impulsive action primarily when levels of premature responding were high (i.e., under a long ITI) but did not affect impulsive choice. Furthermore, using a long ITI in the 5-CSRTT, we show that amphetamine and the DA reuptake blocker GBR12909 enhance, and that atomoxetine and citalopram reduce impulsive action. Thus, the effects of these drugs on impulsive behavior were not qualitatively different under baseline and long ITI conditions. Consistent with previous findings, we also show that amphetamine and the selective dopamine reuptake blocker GBR12909 decreased impulsive choice.

Amphetamine has been consistently reported to disrupt inhibitory control, i.e., the ability to withhold responding in the 5-CSRTT (Cole and Robbins [@CR20]; [@CR21]; Harrison et al. [@CR40]; Murphy et al. [@CR59]; Paterson et al. [@CR66]; Pattij et al. [@CR68]; Sun et al. [@CR86]; Van Gaalen et al. [@CR88]). Our findings confirmed this disinhibitory effect of amphetamine, which increased the number of premature responses in the 5-CSRTT at all doses tested (0.25--1 mg/kg). In addition to response inhibition, the 5-CSRTT provides several relatively independent measures of performance such as task efficiency, motivation and attentional capacity (Robbins [@CR73]). Alongside its effects on premature responding, amphetamine also attenuated accuracy, enhanced perseverative responding, reduced response latency (at 0.5 mg/kg only) and had biphasic effects on errors of omission. The effects of amphetamine were comparable under baseline and long ITI conditions. Although not universally reported as effects of amphetamine in the 5-CSRTT, the present profile of effects is highly comparable to previous reports (reduced accuracy: Cole and Robbins [@CR21]; Harrison et al. [@CR40]; Pattij et al. [@CR68]; Sun et al. [@CR86]; increased omissions: Cole and Robbins [@CR20]; [@CR21]; Harrison et al. [@CR40]; Murphy et al. [@CR59]; Sun et al. [@CR86]; Van Gaalen et al. [@CR88]; and faster response latency: Cole and Robbins [@CR20]; [@CR21]; Harrison et al. [@CR40]; Pattij et al. [@CR68]).

Amphetamine increases extracellular levels of DA, NA, and, to a lesser extent, 5-HT by binding to monoamine transporters on the cell membrane and on intracellular neurotransmitter storage vesicles as a false substrate thereby promoting reverse transport of cytosolic transmitter stores (Seiden et al. [@CR77]; Sulzer et al. [@CR85]). Comparable to amphetamine, GBR12909 also enhanced premature responding, reduced accuracy, enhanced perseverative responding and reduced response latencies under both baseline and long ITI conditions. This indicates that the effects of amphetamine in the 5-CSRTT---except for the increases in errors of omission at the highest dose---are mediated by DA (Fernando et al. [@CR36]; Seu et al. [@CR78]; Van Gaalen et al. [@CR88]). Pharmacological studies have shown that the amphetamine-induced augmentation of premature responding in the 5-CSRTT largely depends on DA D2 receptor stimulation in the nucleus accumbens (Cole and Robbins [@CR21]; Pattij et al. [@CR68]; Van Gaalen et al. [@CR88]; [@CR90]). Conversely, reducing DA neurotransmission using DA receptor antagonists or low doses of DA D2 receptor agonists, which suppress DA neurotransmission by stimulating presynaptic D2 autoreceptors, has been found to reduce impulsive action in the 5-CSRTT (Fernando et al. [@CR36]; Koskinen and Sirvio [@CR44]; Lecourtier and Kelly [@CR49]; Passetti et al. [@CR65]; Van Gaalen et al. [@CR88]; Winstanley et al. [@CR98]). DA-mediated increases in the salience of the reward-related cues in the task and/or increased response vigor by amphetamine may explain its effects in the 5-CSRTT (Berridge and Robinson [@CR7]; Cardinal et al. [@CR16]). This results in a higher rate of performance reflected by a lower amount of errors of omission and faster response latency, albeit at the expense of task accuracy and reduced impulse control. This is consistent with the well-established effect of psychostimulant drugs on behavior, i.e., a general enhancement of the rate of behavioral performance causing short and simple behaviors to dominate the behavioral repertoire and cutting short of complex chains of behavior (Lyon and Robbins [@CR52]). At the highest dose of amphetamine (1 mg/kg), this results in a more general disruption of task performance in the 5-CSRTT. Interestingly, the increase in errors of omission at this highest dose likely relies on NA rather than DA neurotransmission because this effect was mimicked by atomoxetine but not GBR12909. This indicates that at higher doses, the effects of amphetamine on 5-CSRTT performance are mediated by increases in both DA and NA neurotransmission.

Neurobiological and pharmacological data provide evidence for the hypothesis that NA plays a key role in both the etiology and treatment of ADHD (Arnsten, 2009; Biederman and Spencer [@CR9]). Moreover, clinical observations have shown that a subgroup of patients who do not respond to psychostimulants, such as amphetamine and methylphenidate, do respond to atomoxetine (Newcorn et al. [@CR61]). Selective inhibition of NA reuptake by atomoxetine reduced premature responding in the 5-CSRTT under long ITI conditions. NA neurotransmission has been implicated in the regulation of behavior under novel or demanding circumstances (Aston-Jones and Cohen [@CR3]; Cole and Robbins [@CR22]; Dalley et al. [@CR25]; McGaughy et al. [@CR54]; Sirviö et al. [@CR80]). In the 5-CSRTT, PFC NA levels rise when task contingencies are changed (Dalley et al. [@CR25]), and cortically NA-depleted rats are slower to adapt to changing task requirements (Milstein et al. [@CR55]). Our observation that atomoxetine was predominantly effective under (relatively) novel and challenging, long ITI conditions corresponds with these findings. Interestingly, previous studies that reported reduced impulsivity in the 5-CSRTT under baseline conditions after atomoxetine treatment used a shorter stimulus duration (0.5 s versus 1 s in the present study; Blondeau and Dellu-Hagedorn [@CR11]; Robinson et al. [@CR74]; Sun et al. [@CR86]). Under these more demanding test conditions, levels of premature responses are higher, and performance may depend on NA signaling to a greater extent. An alternative, not necessarily inconsistent explanation, is that the absence of an effect of atomoxetine on impulsivity under baseline conditions in our study was due to a floor effect so that the increase in premature responses under long ITI conditions provided a larger window to observe a decrease in impulsivity. Interestingly, atomoxetine indeed seems to reduce impulsive action in the 5-CSRTT primarily in rats characterized by high levels of premature responses (Blondeau and Dellu-Hagedorn [@CR11]; Fernando et al. [@CR36]) or high levels of premature responding due to prolonged ITI durations (Navarra et al. [@CR60]; Paterson et al. [@CR66]). In these studies, no effect of selective blockade of NA by atomoxetine on impulsive action was observed in low impulsive rats (Fernando et al. [@CR36]), efficient rats (Blondeau and Dellu-Hagedorn [@CR11]) or at short intertrial interval durations (4- and 5-s ITI: Paterson et al. [@CR66]; Navarra et al. [@CR60]) consistently reflected by low baseline levels of premature responding.

Atomoxetine also increased errors of omission and lengthened response latencies, under both baseline and long ITI conditions, suggesting that this drug somewhat slowed down the performance in the 5-CSRTT. These effects of atomoxetine are consistent with previous findings with noradrenaline reuptake inhibitors, especially at higher doses (Blondeau and Dellu-Hagedorn [@CR11]; Fernando et al. [@CR36]; Navarra et al. [@CR60]; Paine et al. [@CR64]; Sun et al. [@CR86]; Van Gaalen et al. [@CR88]). Motivational deficits do not likely underlie these increased omissions and response latencies because NA reuptake inhibitors have been shown to increase reinforcement rates in differential reinforcement of low responding schedules (O\'Donnell et al. [@CR63]). Interestingly, under the challenging long ITI conditions, accuracy was improved by systemic atomoxetine (see also Navarra et al. [@CR60]) supporting the role of NA neurotransmission in behavioral vigilance (Arnsten [@CR2]; Aston-Jones and Cohen [@CR3]). Together, these data suggest that NA neurotransmission is particularly involved in the modulation of behavior in the 5-CSRTT under circumstances when task performance is suboptimal, either as a result of demanding task requirements or as a result of inherent individual differences in behavior. Increasing NA neurotransmission then leads to a more conservative pattern of responding whereby task accuracy and impulse control increase but speed of performance declines somewhat.

The serotonin reuptake inhibitor citalopram resulted in a decrease in premature responding in the 5-CSRTT at an intermediate dose of 1 mg/kg. A similar improvement in impulse control was observed under long ITI conditions. In contrast to amphetamine, GBR12909 and atomoxetine, the effect of citalopram on premature responding was quite selective as accuracy and errors of omission were not affected. Our finding is in line with the observation that enhanced 5-HT transmission in 5-HT transporter knockout rats is associated with reduced premature responding in the 5-CSRTT (Homberg et al. [@CR42]). Conversely, forebrain 5-HT depletion significantly increases premature responding in the 5-CSRTT (Harrison et al. [@CR40]; Winstanley et al. [@CR96]). Together, these studies suggest that increasing 5-HT activity may be a possible mechanism for attenuation of impulsive action. In vivo microdialysis within the medial prefrontal cortex has shown a positive relationship between premature responding and basal 5-HT levels although no alteration in 5-HT efflux during task performance was found (Dalley et al. [@CR26]). These results indicate a role for tonic 5-HT levels in the prefrontal cortex in impulsive regulation in the 5-CSRTT. However, 5-HT depletion using 5,7-DHT infusion into the medial prefrontal cortex did not affect impulsive action in the 5-CSRTT (Fletcher et al. [@CR37]). Thus, the role of 5-HT in impulse action is not straightforward, which is likely related to the great diversity of 5-HT receptors, and the fact that 5-HT modulates impulsive action through different brain regions (Eagle and Baunez [@CR32]; Pattij and Vanderschuren [@CR67]).

In contrast to its effects on impulsive behavior in the 5CSRTT, amphetamine had beneficial effects on impulsive choice, exemplified by the enhanced ability of the animals to choose a large, delayed reward instead of a small, immediate reward. Our finding is in keeping with previous studies in mice, rats and humans (Barbelivien et al. [@CR5]; De Wit et al. [@CR29]; Isles et al. [@CR43]; Richards et al. [@CR71]; Van Gaalen et al. [@CR89]; Wade et al. [@CR92]; Winstanley et al. [@CR95]) although this effect of amphetamine is found to be dose-, baseline- and context-dependent (Barbelivien et al. [@CR5]; Cardinal et al. [@CR15]; Evenden and Ryan [@CR35]; Isles et al. [@CR43]). In this study, we showed that impulsive choice was decreased after blockade of DA by GBR12909 but not selective blockade of NA or 5-HT by atomoxetine or citalopram, respectively. An important regulatory role of DA in impulsive choice has been proposed before (Wade et al. [@CR92]; Van Gaalen et al. [@CR89]) as the improved impulsive choice by amphetamine was blocked by the DA D2 receptor antagonist eticlopride (Van Gaalen et al. [@CR89]).

In the present study, atomoxetine did not affect impulsive choice. In agreement with our findings, Sun et al. ([@CR86]) found no effect on impulsive choice following atomoxetine administration. In contrast, Robinson et al. ([@CR74]) reported that atomoxetine reduced impulsive choice whereby the increase in percentage choice for the large reward after atomoxetine treatment was most pronounced at the shorter delays. The somewhat less selective NA reuptake blocker desipramine had no consistent effect in the DRT (Van Gaalen et al. [@CR89]). Together, these data suggest that acute enhancement of NA neurotransmission has, at best, modest effects on impulsive choice in a delayed reward task.

In vivo microdialysis experiments have shown that 5-HT release within the medial prefrontal cortex correlates with performance in the DRT (Winstanley et al. [@CR97]) indicating that 5-HT release is essential for proper delay discounting judgments. However, inconsistent effects of forebrain 5-HT depletions on impulsive choice have been found (Bizot et al. [@CR10]; Mobini et al. [@CR56]; Winstanley et al. [@CR95]; [@CR96]; Wogar et al. [@CR99]). Likewise, inconsistent effects of 5-HT depletion have been found in humans as tryptophan depletion increased delay discounting in healthy volunteers in one study (Schweighofer et al. [@CR76]) but not another (Crean et al. [@CR24]). In the present study, selective inhibition of 5-HT reuptake by citalopram did not affect choice behavior in the delayed reward task. In agreement with our findings, Evenden and Ryan ([@CR35]) found that the tolerance to delay of gratification was not affected by acute administration of citalopram or imipramine. Early studies on the neural mechanisms of impulsive behavior have implicated low levels of 5-HT in impulsivity (Linnoila et al. [@CR50]; Soubrié [@CR83]). Together with previous findings discussed here, our data indicate that elevation of 5-HT levels by SSRIs has a beneficial effect on impulsive action but not impulsive choice suggesting that the early association of 5-HT with impulsivity relates more to the former than to the latter.

The present study aimed to pinpoint the separate roles of three monoamine neurotransmitters in two forms of impulsive behavior using selective DA, NA and 5-HT reuptake blockers. Two limitations to this approach should be mentioned. First, although GBR12909, atomoxetine and citalopram display low affinity for the other monoamine transporters (Fone and Nutt [@CR38]; Rothman et al. [@CR75]), transporter-selective reuptake inhibitors are not necessarily transmitter-selective reuptake inhibitors. DA reuptake in the striatum depends primarily on the DA transporter, whereas DA reuptake in the prefrontal cortex depends on both the NA transporter and the DA transporter due to the low density of the DA transporter in this area (Carboni et al. [@CR14]; Morón et al. [@CR58]; Tanda et al. [@CR87]). Atomoxetine, therefore, indirectly boosts prefrontal cortical DA via its effects on the NA transporter but it does not modulate DA levels in the striatum (Bymaster et al. [@CR13]). Thus, a contribution of prefrontal DA to the effects of atomoxetine in the 5-CSRTT cannot be excluded. However, the COMT inhibitor tolcapone that selectively modulates DA, but not NA, did not attenuate impulsive action in rats that exhibited suboptimal 5-CSRTT performance suggesting that cortical DA does not contribute to the effects of atomoxetine on impulsive action (Paterson et al. [@CR66]). Second, through their downstream effects, increased synaptic DA, NA and 5-HT levels can indirectly alter the activity of other neurotransmitter systems (e.g., Di Giovanni et al. [@CR30]; Vanderschuren et al. [@CR91]) so that coordinated activity of multiple neurotransmitter systems mediates adaptive behavior. For example, with regard to impulse control, 5-HT--DA interactions have been shown to be involved in impulsive choice in rats. Thus, forebrain 5-HT lesions attenuated the ability of amphetamine to decrease impulsive behavior in a delay-discounting task, particularly in rats with high baseline levels of impulsivity, but did not themselves alter delay-discounting performance (Winstanley et al. [@CR95]). Therefore, involvement of neurotransmitters other than DA, NA and 5-HT, respectively, in the behavioral effects of GBR12909, atomoxetine and citalopram cannot be excluded.

In conclusion, the neuropharmacological manipulations presented here indicate a differential contribution of DA, NA and 5-HT in the modulation of two dimensions of impulsivity. Inhibition of the reuptake of DA exerted opposite effects on impulsive action (increase) and impulsive choice (decrease), whereas inhibition of NA and 5-HT reuptake reduced impulsive action but not impulsive choice. The current study, therefore, supports the well-established notion of the heterogenous nature of impulsivity (Dalley et al. [@CR28]; Eagle and Baunez [@CR32]; Evenden [@CR34]; Pattij and Vanderschuren [@CR67]). The existence of independent processes of impulse control is exemplified in the psychiatric population, although it is difficult to relate certain forms of impulsivity with particular disorders (Moeller et al. [@CR57]; Solanto et al. [@CR81]; Sonuga-Barke [@CR82]). Nevertheless, deficits in one of the subtypes of impulsivity or genetic variation in monoamine signaling (e.g., Colzato et al. [@CR23]; Hamidovic et al. [@CR39]) may contribute to the differential responsiveness and effectiveness of drug treatments in impulse control disorders. As such, understanding the contribution of different neurotransmitter systems to distinct forms of impulsivity may contribute to the development of selectively tailored pharmacotherapeutic treatments of impulse control disorders.
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